Current Trends in the Pharmacotherapy of Cataracts
- PMID: 31963166
- PMCID: PMC7168925
- DOI: 10.3390/ph13010015
Current Trends in the Pharmacotherapy of Cataracts
Erratum in
-
Correction: Heruye et al. Current Trends in the Pharmacotherapy of Cataracts. Pharmaceuticals 2020, 13, 15.Pharmaceuticals (Basel). 2024 Jul 15;17(7):947. doi: 10.3390/ph17070947. Pharmaceuticals (Basel). 2024. PMID: 39065822 Free PMC article.
Abstract
Cataracts, one of the leading causes of preventable blindness worldwide, refers to lens degradation that is characterized by clouding, with consequent blurry vision. As life expectancies improve, the number of people affected with cataracts is predicted to increase worldwide, especially in low-income nations with limited access to surgery. Although cataract surgery is considered safe, it is associated with some complications such as retinal detachment, warranting a search for cheap, pharmacological alternatives to the management of this ocular disease. The lens is richly endowed with a complex system of non-enzymatic and enzymatic antioxidants which scavenge reactive oxygen species to preserve lens proteins. Depletion and/or failure in this primary antioxidant defense system contributes to the damage observed in lenticular molecules and their repair mechanisms, ultimately causing cataracts. Several attempts have been made to counteract experimentally induced cataract using in vitro, ex vivo, and in vivo techniques. The majority of the anti-cataract compounds tested, including plant extracts and naturally-occurring compounds, lies in their antioxidant and/or free radical scavenging and/or anti-inflammatory propensity. In addition to providing an overview of the pathophysiology of cataracts, this review focuses on the role of various categories of natural and synthetic compounds on experimentally-induced cataracts.
Keywords: antioxidants; cataracts; glutathione; lens; lens crystallins; lens opacification; lens transparency; superoxide dismutase.
Conflict of interest statement
The authors declare no conflict of interest.
Figures



Similar articles
-
Generation of reactive oxygen species in the anterior eye segment. Synergistic codrugs of N-acetylcarnosine lubricant eye drops and mitochondria-targeted antioxidant act as a powerful therapeutic platform for the treatment of cataracts and primary open-angle glaucoma.BBA Clin. 2016 Apr 19;6:49-68. doi: 10.1016/j.bbacli.2016.04.004. eCollection 2016 Dec. BBA Clin. 2016. PMID: 27413694 Free PMC article. Review.
-
Reactive Oxygen Species and the Aging Eye: Specific Role of Metabolically Active Mitochondria in Maintaining Lens Function and in the Initiation of the Oxidation-Induced Maturity Onset Cataract--A Novel Platform of Mitochondria-Targeted Antioxidants With Broad Therapeutic Potential for Redox Regulation and Detoxification of Oxidants in Eye Diseases.Am J Ther. 2016 Jan-Feb;23(1):e98-117. doi: 10.1097/MJT.0b013e3181ea31ff. Am J Ther. 2016. PMID: 21048433 Review.
-
Cataract Surgery.2023 Jul 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2023 Jul 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32644679 Free Books & Documents.
-
Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes.Drugs R D. 2004;5(3):125-39. doi: 10.2165/00126839-200405030-00001. Drugs R D. 2004. PMID: 15139774 Review.
-
Potentiation of intraocular absorption and drug metabolism of N-acetylcarnosine lubricant eye drops: drug interaction with sight threatening lipid peroxides in the treatment for age-related eye diseases.Drug Metabol Drug Interact. 2009;24(2-4):275-323. doi: 10.1515/dmdi.2009.24.2-4.275. Drug Metabol Drug Interact. 2009. PMID: 20408504
Cited by
-
Quantitative and Rapid In Vivo Imaging of Human Lenticular Fluorescence.Invest Ophthalmol Vis Sci. 2024 Nov 4;65(13):41. doi: 10.1167/iovs.65.13.41. Invest Ophthalmol Vis Sci. 2024. PMID: 39565304 Free PMC article.
-
Predictors of time to recovery from cataract surgery among cataract patients at Menelik II Comprehensive Specialized Hospital: a retrospective follow up study.BMC Ophthalmol. 2025 Apr 25;25(1):246. doi: 10.1186/s12886-025-04053-4. BMC Ophthalmol. 2025. PMID: 40281445 Free PMC article.
-
Chitosan and Anionic Solubility Enhancer Sulfobutylether-β-Cyclodextrin-Based Nanoparticles as Dexamethasone Ophthalmic Delivery System for Anti-Inflammatory Therapy.Pharmaceutics. 2024 Feb 16;16(2):277. doi: 10.3390/pharmaceutics16020277. Pharmaceutics. 2024. PMID: 38399331 Free PMC article.
-
Burden of cataracts in developing countries: a trend analysis based on data from China, 1990 to 2021.Front Med (Lausanne). 2025 Apr 29;12:1550788. doi: 10.3389/fmed.2025.1550788. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40365490 Free PMC article.
-
Characterization and Bioactive Potential of Carotenoid Lutein from Gordonia rubripertncta GH-1 Isolated from Traditional Pixian Douban.Foods. 2022 Nov 15;11(22):3649. doi: 10.3390/foods11223649. Foods. 2022. PMID: 36429243 Free PMC article.
References
-
- Khairallah M., Kahloun R., Bourne R., Limburg H., Flaxman S.R., Jonas J.B., Keeffe J., Leasher J., Naidoo K., Pesudovs K., et al. Number of people blind or visually impaired by cataract worldwide and in world regions, 1990 to 2010. Investig. Ophthalmol. Vis. Sci. 2015;56:6762–6769. doi: 10.1167/iovs.15-17201. - DOI - PubMed
-
- Chua J., Koh J.Y., Tan A.G., Zhao W., Lamoureux E., Mitchell P., Wang J.J., Wong T.Y., Cheng C.Y. Ancestry, socioeconomic status, and age-related cataract in Asians: The Singapore Epidemiology of Eye Diseases Study. Ophthalmology. 2015;122:2169–2178. doi: 10.1016/j.ophtha.2015.06.052. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials